Clinical Trial

Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

Study acronym: ASPIRE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\] and risk of adverse outcomes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-21.
Trial Details
NCT Number NCT07669935
Lead Sponsor Medicines360
Conditions GDM, Preterm Preeclampsia, Preeclampsia, Fetal Growth Restriction (FGR), Pregnancy Complications
Enrollment 5,500 participants
Start Date 2026-07-30
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29